Wall Street still prices Abbott like a dividend stalwart, but overlooked moves suggest that framing may be costing investors ...
Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes.
BTIG analyst Marie Thibault maintained a Buy rating on Dexcom on July 10 and set a price target of $80.00. The company’s shares closed yesterday at $74.96. TipRanks Welcomes a New ETF – NYSE:RANK ...
DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with ...
Health Canada has granted authorisation for the Dexcom G7 15 Day continuous glucose monitor (CGM) for adults aged 18 years ...
Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...
4d
Influencers are hopping on a surprising wearable trend that requires a needle — do you need one?
Healthy influencers are embracing a wearable once reserved for diabetes patients to optimize their health. But experts say ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results